Which has better valuation & earnings, IVA or ARQT?

Arcutis Biotherapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 159.85 -$400.67M N/A N/A Arcutis Biotherapeutics $463.98M 7.15 -$16.14M $0.21 125.62

Does the media favor IVA or ARQT?

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 3 mentions for Inventiva. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Inventiva's score of 0.24 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, MBX or IVA?

MBX Biosciences has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.41 N/A Inventiva $4.48M 159.85 -$400.67M N/A N/A

Is MBX or IVA more profitable?

Inventiva's return on equity of 0.00% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.02% -24.94% Inventiva N/A N/A N/A

Does the media prefer MBX or IVA?

In the previous week, Inventiva had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.07 beat Inventiva's score of 0.24 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MOR or IVA?

Inventiva has a consensus price target of $15.75, indicating a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Inventiva 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09

Which has higher valuation & earnings, MOR or IVA?

MorphoSys has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Inventiva $4.48M 159.85 -$400.67M N/A N/A

Is MOR or IVA more profitable?

Inventiva has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Inventiva's return on equity of 0.00% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Inventiva N/A N/A N/A

Do analysts rate IVA or RGC?

Inventiva presently has a consensus target price of $15.75, indicating a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher possible upside, equities analysts clearly believe Inventiva is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, IVA or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 159.85 -$400.67M N/A N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is IVA or RGC more profitable?

Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Regencell Bioscience N/A N/A N/A

Does the media favor IVA or RGC?

In the previous week, Inventiva had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Regencell Bioscience. Inventiva's average media sentiment score of 0.24 beat Regencell Bioscience's score of -0.95 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has better valuation & earnings, ATAI or IVA?

Inventiva has higher revenue and earnings than Atai Beckley. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 666.46 -$660.05M -$2.18 N/A Inventiva $4.48M 159.85 -$400.67M N/A N/A

Inventiva (IVA) Competitors

$3.45 -0.20 (-5.48%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.38 -0.07 (-1.91%)

As of 04:49 AM Eastern

Compare

IVA vs. ARQT, MBX, MOR, RGC, and ATAI

Should you buy Inventiva stock or one of its competitors? Inventiva's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), MorphoSys (MOR), Regencell Bioscience (RGC), and Atai Beckley (ATAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inventiva compare to Arcutis Biotherapeutics?

Inventiva (NASDAQ:IVA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

19.1% of Inventiva shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Inventiva has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Inventiva's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Arcutis Biotherapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A
Arcutis Biotherapeutics	$463.98M	7.15	-$16.14M	$0.21	125.62

Inventiva presently has a consensus target price of $15.75, indicating a potential upside of 356.52%. Arcutis Biotherapeutics has a consensus target price of $35.57, indicating a potential upside of 34.84%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 3 mentions for Inventiva. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Inventiva's score of 0.24 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arcutis Biotherapeutics beats Inventiva on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Inventiva had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.07 beat Inventiva's score of 0.24 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MBX Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

Inventiva's return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Inventiva	N/A	N/A	N/A

MBX Biosciences currently has a consensus target price of $77.00, indicating a potential upside of 33.01%. Inventiva has a consensus target price of $15.75, indicating a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

MBX Biosciences has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A

Summary

Inventiva beats MBX Biosciences on 10 of the 13 factors compared between the two stocks.

How does Inventiva compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Inventiva has a consensus price target of $15.75, indicating a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inventiva has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Inventiva's return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Inventiva	N/A	N/A	N/A

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

MorphoSys has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A

In the previous week, Inventiva had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Inventiva and 0 mentions for MorphoSys. Inventiva's average media sentiment score of 0.24 beat MorphoSys' score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Inventiva	Neutral

Summary

Inventiva beats MorphoSys on 12 of the 15 factors compared between the two stocks.

How does Inventiva compare to Regencell Bioscience?

Inventiva (NASDAQ:IVA) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Regencell Bioscience has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Regencell Bioscience	N/A	N/A	N/A

Inventiva has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Inventiva presently has a consensus target price of $15.75, indicating a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher possible upside, equities analysts clearly believe Inventiva is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Inventiva had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Regencell Bioscience. Inventiva's average media sentiment score of 0.24 beat Regencell Bioscience's score of -0.95 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Inventiva beats Regencell Bioscience on 9 of the 11 factors compared between the two stocks.

How does Inventiva compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Atai Beckley presently has a consensus price target of $10.56, suggesting a potential upside of 43.62%. Inventiva has a consensus price target of $15.75, suggesting a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Inventiva has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Inventiva's return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Inventiva	N/A	N/A	N/A

In the previous week, Inventiva had 3 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Inventiva and 0 mentions for Atai Beckley. Inventiva's average media sentiment score of 0.24 beat Atai Beckley's score of 0.24 indicating that Inventiva is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Neutral
Inventiva	Neutral

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

Inventiva has higher revenue and earnings than Atai Beckley.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Inventiva beats Atai Beckley on 12 of the 15 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$758.13M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	N/A	792.28	274.09	25.69
Price / Sales	159.85	861.37	642.55	79.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	-15.68	10.58	10.47	6.32
Net Income	-$400.67M	$2.81B	$3.49B	$359.73M
7 Day Performance	-8.00%	-0.12%	-0.68%	0.17%
1 Month Performance	-26.60%	-1.34%	-3.18%	-3.27%
1 Year Performance	-37.50%	2.86%	15.12%	5.58%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	2.6127 of 5 stars	$3.45 -5.5%	$15.75 +356.5%	-39.2%	$758.13M	$4.48M	N/A	73	Upcoming Earnings
ARQT Arcutis Biotherapeutics	3.8113 of 5 stars	$23.54 -3.0%	$35.57 +51.1%	+49.9%	$2.96B	$463.98M	112.19	354
MBX MBX Biosciences	2.8195 of 5 stars	$59.93 +0.7%	$77.00 +28.5%	+205.3%	$2.89B	N/A	N/A	63
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RGC Regencell Bioscience	0.1127 of 5 stars	$5.66 -1.4%	N/A	-59.5%	$2.80B	N/A	N/A	10	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. ARQT, MBX, MOR, RGC, and ATAI

How does Inventiva compare to Arcutis Biotherapeutics?

Summary

How does Inventiva compare to MBX Biosciences?

Summary

How does Inventiva compare to MorphoSys?

Summary

How does Inventiva compare to Regencell Bioscience?

Summary

How does Inventiva compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. ARQT, MBX, MOR, RGC, and ATAI

How does Inventiva compare to Arcutis Biotherapeutics?

Do institutionals and insiders believe in IVA or ARQT?

Which has more risk and volatility, IVA or ARQT?

Is IVA or ARQT more profitable?

Which has better valuation & earnings, IVA or ARQT?

Do analysts prefer IVA or ARQT?

Does the media favor IVA or ARQT?

Summary

How does Inventiva compare to MBX Biosciences?

Does the media prefer MBX or IVA?

Do insiders & institutionals have more ownership in MBX or IVA?

Which has more volatility & risk, MBX or IVA?

Is MBX or IVA more profitable?

Do analysts prefer MBX or IVA?

Which has better earnings & valuation, MBX or IVA?

Summary

How does Inventiva compare to MorphoSys?

Do analysts prefer MOR or IVA?

Do institutionals and insiders have more ownership in MOR or IVA?

Is MOR or IVA more profitable?

Which has more risk and volatility, MOR or IVA?

Which has higher valuation & earnings, MOR or IVA?

Does the media prefer MOR or IVA?

Summary

How does Inventiva compare to Regencell Bioscience?

Which has better earnings and valuation, IVA or RGC?

Do institutionals and insiders believe in IVA or RGC?

Is IVA or RGC more profitable?

Which has more volatility & risk, IVA or RGC?

Do analysts rate IVA or RGC?

Does the media favor IVA or RGC?

Summary

How does Inventiva compare to Atai Beckley?

Do analysts recommend ATAI or IVA?

Is ATAI or IVA more profitable?

Does the media prefer ATAI or IVA?

Which has more volatility & risk, ATAI or IVA?

Which has better valuation & earnings, ATAI or IVA?

Do institutionals & insiders hold more shares of ATAI or IVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools